nodes	percent_of_prediction	percent_of_DWPC	metapath
Solifenacin—Benazepril—Lisinopril—systemic scleroderma	0.759	1	CrCrCtD
Solifenacin—Benazepril—ACE—systemic scleroderma	0.00342	1	CrCbGaD
Solifenacin—Dizziness—Pentoxifylline—systemic scleroderma	0.000442	0.00186	CcSEcCtD
Solifenacin—Hypertension—Leflunomide—systemic scleroderma	0.000441	0.00186	CcSEcCtD
Solifenacin—Decreased appetite—Captopril—systemic scleroderma	0.00044	0.00185	CcSEcCtD
Solifenacin—Hallucination—Mycophenolate mofetil—systemic scleroderma	0.00044	0.00185	CcSEcCtD
Solifenacin—Malnutrition—Lisinopril—systemic scleroderma	0.000439	0.00185	CcSEcCtD
Solifenacin—Infection—Azathioprine—systemic scleroderma	0.000439	0.00185	CcSEcCtD
Solifenacin—Pharyngitis—Mycophenolate mofetil—systemic scleroderma	0.000439	0.00185	CcSEcCtD
Solifenacin—Urinary tract disorder—Mycophenolate mofetil—systemic scleroderma	0.000437	0.00184	CcSEcCtD
Solifenacin—Fatigue—Captopril—systemic scleroderma	0.000436	0.00184	CcSEcCtD
Solifenacin—Oedema peripheral—Mycophenolate mofetil—systemic scleroderma	0.000436	0.00183	CcSEcCtD
Solifenacin—Connective tissue disorder—Mycophenolate mofetil—systemic scleroderma	0.000434	0.00183	CcSEcCtD
Solifenacin—Urethral disorder—Mycophenolate mofetil—systemic scleroderma	0.000433	0.00182	CcSEcCtD
Solifenacin—Constipation—Captopril—systemic scleroderma	0.000433	0.00182	CcSEcCtD
Solifenacin—Unspecified disorder of skin and subcutaneous tissue—Leflunomide—systemic scleroderma	0.000432	0.00182	CcSEcCtD
Solifenacin—Palpitations—Mycophenolic acid—systemic scleroderma	0.000431	0.00181	CcSEcCtD
Solifenacin—Dysgeusia—Lisinopril—systemic scleroderma	0.00043	0.00181	CcSEcCtD
Solifenacin—Skin disorder—Azathioprine—systemic scleroderma	0.000429	0.0018	CcSEcCtD
Solifenacin—Dry mouth—Leflunomide—systemic scleroderma	0.000426	0.00179	CcSEcCtD
Solifenacin—Cough—Mycophenolic acid—systemic scleroderma	0.000426	0.00179	CcSEcCtD
Solifenacin—Vomiting—Pentoxifylline—systemic scleroderma	0.000425	0.00179	CcSEcCtD
Solifenacin—Rash—Pentoxifylline—systemic scleroderma	0.000421	0.00177	CcSEcCtD
Solifenacin—Hypertension—Mycophenolic acid—systemic scleroderma	0.000421	0.00177	CcSEcCtD
Solifenacin—Dermatitis—Pentoxifylline—systemic scleroderma	0.000421	0.00177	CcSEcCtD
Solifenacin—Headache—Pentoxifylline—systemic scleroderma	0.000418	0.00176	CcSEcCtD
Solifenacin—Anaphylactic shock—Leflunomide—systemic scleroderma	0.000417	0.00175	CcSEcCtD
Solifenacin—Feeling abnormal—Captopril—systemic scleroderma	0.000417	0.00175	CcSEcCtD
Solifenacin—Infection—Leflunomide—systemic scleroderma	0.000414	0.00174	CcSEcCtD
Solifenacin—Vision blurred—Lisinopril—systemic scleroderma	0.000414	0.00174	CcSEcCtD
Solifenacin—Gastrointestinal pain—Captopril—systemic scleroderma	0.000414	0.00174	CcSEcCtD
Solifenacin—Asthenia—Mometasone—systemic scleroderma	0.000414	0.00174	CcSEcCtD
Solifenacin—Eye disorder—Mycophenolate mofetil—systemic scleroderma	0.000413	0.00174	CcSEcCtD
Solifenacin—Unspecified disorder of skin and subcutaneous tissue—Mycophenolic acid—systemic scleroderma	0.000412	0.00173	CcSEcCtD
Solifenacin—Cardiac disorder—Mycophenolate mofetil—systemic scleroderma	0.00041	0.00173	CcSEcCtD
Solifenacin—Nervous system disorder—Leflunomide—systemic scleroderma	0.000409	0.00172	CcSEcCtD
Solifenacin—Pruritus—Mometasone—systemic scleroderma	0.000408	0.00172	CcSEcCtD
Solifenacin—Tachycardia—Leflunomide—systemic scleroderma	0.000407	0.00171	CcSEcCtD
Solifenacin—Dry mouth—Mycophenolic acid—systemic scleroderma	0.000406	0.00171	CcSEcCtD
Solifenacin—Skin disorder—Leflunomide—systemic scleroderma	0.000405	0.0017	CcSEcCtD
Solifenacin—Angioedema—Lisinopril—systemic scleroderma	0.000401	0.00169	CcSEcCtD
Solifenacin—Confusional state—Mycophenolic acid—systemic scleroderma	0.000401	0.00169	CcSEcCtD
Solifenacin—Angiopathy—Mycophenolate mofetil—systemic scleroderma	0.000401	0.00169	CcSEcCtD
Solifenacin—Abdominal pain—Captopril—systemic scleroderma	0.0004	0.00168	CcSEcCtD
Solifenacin—Mediastinal disorder—Mycophenolate mofetil—systemic scleroderma	0.000398	0.00168	CcSEcCtD
Solifenacin—Dry skin—Prednisone—systemic scleroderma	0.000397	0.00167	CcSEcCtD
Solifenacin—Nausea—Pentoxifylline—systemic scleroderma	0.000397	0.00167	CcSEcCtD
Solifenacin—Infection—Mycophenolic acid—systemic scleroderma	0.000395	0.00166	CcSEcCtD
Solifenacin—Nervous system disorder—Mycophenolic acid—systemic scleroderma	0.00039	0.00164	CcSEcCtD
Solifenacin—Tachycardia—Mycophenolic acid—systemic scleroderma	0.000388	0.00163	CcSEcCtD
Solifenacin—Palpitations—Lisinopril—systemic scleroderma	0.000388	0.00163	CcSEcCtD
Solifenacin—Mental disorder—Mycophenolate mofetil—systemic scleroderma	0.000387	0.00163	CcSEcCtD
Solifenacin—Skin disorder—Mycophenolic acid—systemic scleroderma	0.000387	0.00163	CcSEcCtD
Solifenacin—Malnutrition—Mycophenolate mofetil—systemic scleroderma	0.000385	0.00162	CcSEcCtD
Solifenacin—Dermatitis exfoliative—Methotrexate—systemic scleroderma	0.000384	0.00161	CcSEcCtD
Solifenacin—Cough—Lisinopril—systemic scleroderma	0.000383	0.00161	CcSEcCtD
Solifenacin—Muscular weakness—Prednisone—systemic scleroderma	0.000382	0.00161	CcSEcCtD
Solifenacin—Gastrointestinal disorder—Azathioprine—systemic scleroderma	0.000381	0.0016	CcSEcCtD
Solifenacin—Dysgeusia—Mycophenolate mofetil—systemic scleroderma	0.000377	0.00159	CcSEcCtD
Solifenacin—Unspecified disorder of skin and subcutaneous tissue—Lisinopril—systemic scleroderma	0.000371	0.00156	CcSEcCtD
Solifenacin—Dyspepsia—Leflunomide—systemic scleroderma	0.000367	0.00154	CcSEcCtD
Solifenacin—Vomiting—Mometasone—systemic scleroderma	0.000366	0.00154	CcSEcCtD
Solifenacin—Dry mouth—Lisinopril—systemic scleroderma	0.000366	0.00154	CcSEcCtD
Solifenacin—Feeling abnormal—Azathioprine—systemic scleroderma	0.000364	0.00153	CcSEcCtD
Solifenacin—Rash—Mometasone—systemic scleroderma	0.000363	0.00153	CcSEcCtD
Solifenacin—Asthenia—Captopril—systemic scleroderma	0.000363	0.00153	CcSEcCtD
Solifenacin—Dermatitis—Mometasone—systemic scleroderma	0.000363	0.00153	CcSEcCtD
Solifenacin—Decreased appetite—Leflunomide—systemic scleroderma	0.000363	0.00153	CcSEcCtD
Solifenacin—Confusional state—Lisinopril—systemic scleroderma	0.000361	0.00152	CcSEcCtD
Solifenacin—Gastrointestinal pain—Azathioprine—systemic scleroderma	0.000361	0.00152	CcSEcCtD
Solifenacin—Headache—Mometasone—systemic scleroderma	0.000361	0.00152	CcSEcCtD
Solifenacin—Gastrointestinal disorder—Leflunomide—systemic scleroderma	0.00036	0.00152	CcSEcCtD
Solifenacin—Fatigue—Leflunomide—systemic scleroderma	0.00036	0.00151	CcSEcCtD
Solifenacin—Anaphylactic shock—Lisinopril—systemic scleroderma	0.000358	0.00151	CcSEcCtD
Solifenacin—Pruritus—Captopril—systemic scleroderma	0.000358	0.00151	CcSEcCtD
Solifenacin—Constipation—Leflunomide—systemic scleroderma	0.000357	0.0015	CcSEcCtD
Solifenacin—Infection—Lisinopril—systemic scleroderma	0.000356	0.0015	CcSEcCtD
Solifenacin—Somnolence—Mycophenolic acid—systemic scleroderma	0.000354	0.00149	CcSEcCtD
Solifenacin—Angioedema—Mycophenolate mofetil—systemic scleroderma	0.000352	0.00148	CcSEcCtD
Solifenacin—Dyspepsia—Mycophenolic acid—systemic scleroderma	0.00035	0.00147	CcSEcCtD
Solifenacin—Tachycardia—Lisinopril—systemic scleroderma	0.00035	0.00147	CcSEcCtD
Solifenacin—Abdominal pain—Azathioprine—systemic scleroderma	0.000349	0.00147	CcSEcCtD
Solifenacin—Skin disorder—Lisinopril—systemic scleroderma	0.000348	0.00146	CcSEcCtD
Solifenacin—Decreased appetite—Mycophenolic acid—systemic scleroderma	0.000346	0.00146	CcSEcCtD
Solifenacin—Feeling abnormal—Leflunomide—systemic scleroderma	0.000344	0.00145	CcSEcCtD
Solifenacin—Gastrointestinal disorder—Mycophenolic acid—systemic scleroderma	0.000344	0.00145	CcSEcCtD
Solifenacin—Fatigue—Mycophenolic acid—systemic scleroderma	0.000343	0.00144	CcSEcCtD
Solifenacin—Nausea—Mometasone—systemic scleroderma	0.000342	0.00144	CcSEcCtD
Solifenacin—Gastrointestinal pain—Leflunomide—systemic scleroderma	0.000341	0.00143	CcSEcCtD
Solifenacin—Constipation—Mycophenolic acid—systemic scleroderma	0.00034	0.00143	CcSEcCtD
Solifenacin—Palpitations—Mycophenolate mofetil—systemic scleroderma	0.00034	0.00143	CcSEcCtD
Solifenacin—Cough—Mycophenolate mofetil—systemic scleroderma	0.000336	0.00141	CcSEcCtD
Solifenacin—Dizziness—Captopril—systemic scleroderma	0.000335	0.00141	CcSEcCtD
Solifenacin—Liver function test abnormal—Methotrexate—systemic scleroderma	0.000334	0.00141	CcSEcCtD
Solifenacin—Depression—Prednisone—systemic scleroderma	0.000333	0.0014	CcSEcCtD
Solifenacin—Hypertension—Mycophenolate mofetil—systemic scleroderma	0.000332	0.0014	CcSEcCtD
Solifenacin—Urticaria—Leflunomide—systemic scleroderma	0.000331	0.00139	CcSEcCtD
Solifenacin—Abdominal pain—Leflunomide—systemic scleroderma	0.00033	0.00139	CcSEcCtD
Solifenacin—Feeling abnormal—Mycophenolic acid—systemic scleroderma	0.000328	0.00138	CcSEcCtD
Solifenacin—Hypersensitivity—Azathioprine—systemic scleroderma	0.000325	0.00137	CcSEcCtD
Solifenacin—Gastrointestinal pain—Mycophenolic acid—systemic scleroderma	0.000325	0.00137	CcSEcCtD
Solifenacin—Unspecified disorder of skin and subcutaneous tissue—Mycophenolate mofetil—systemic scleroderma	0.000325	0.00137	CcSEcCtD
Solifenacin—Vomiting—Captopril—systemic scleroderma	0.000322	0.00135	CcSEcCtD
Solifenacin—Dry mouth—Mycophenolate mofetil—systemic scleroderma	0.00032	0.00135	CcSEcCtD
Solifenacin—Rash—Captopril—systemic scleroderma	0.000319	0.00134	CcSEcCtD
Solifenacin—Dermatitis—Captopril—systemic scleroderma	0.000319	0.00134	CcSEcCtD
Solifenacin—Somnolence—Lisinopril—systemic scleroderma	0.000319	0.00134	CcSEcCtD
Solifenacin—Headache—Captopril—systemic scleroderma	0.000317	0.00133	CcSEcCtD
Solifenacin—Confusional state—Mycophenolate mofetil—systemic scleroderma	0.000317	0.00133	CcSEcCtD
Solifenacin—Dyspepsia—Lisinopril—systemic scleroderma	0.000316	0.00133	CcSEcCtD
Solifenacin—Abdominal pain—Mycophenolic acid—systemic scleroderma	0.000315	0.00132	CcSEcCtD
Solifenacin—Anaphylactic shock—Mycophenolate mofetil—systemic scleroderma	0.000314	0.00132	CcSEcCtD
Solifenacin—Infection—Mycophenolate mofetil—systemic scleroderma	0.000312	0.00131	CcSEcCtD
Solifenacin—Decreased appetite—Lisinopril—systemic scleroderma	0.000312	0.00131	CcSEcCtD
Solifenacin—Gastrointestinal disorder—Lisinopril—systemic scleroderma	0.00031	0.0013	CcSEcCtD
Solifenacin—Fatigue—Lisinopril—systemic scleroderma	0.000309	0.0013	CcSEcCtD
Solifenacin—Nervous system disorder—Mycophenolate mofetil—systemic scleroderma	0.000308	0.0013	CcSEcCtD
Solifenacin—Hypersensitivity—Leflunomide—systemic scleroderma	0.000307	0.00129	CcSEcCtD
Solifenacin—Constipation—Lisinopril—systemic scleroderma	0.000307	0.00129	CcSEcCtD
Solifenacin—Tachycardia—Mycophenolate mofetil—systemic scleroderma	0.000307	0.00129	CcSEcCtD
Solifenacin—Skin disorder—Mycophenolate mofetil—systemic scleroderma	0.000305	0.00128	CcSEcCtD
Solifenacin—Nausea—Captopril—systemic scleroderma	0.000301	0.00126	CcSEcCtD
Solifenacin—Asthenia—Leflunomide—systemic scleroderma	0.000299	0.00126	CcSEcCtD
Solifenacin—Hallucination—Prednisone—systemic scleroderma	0.000298	0.00125	CcSEcCtD
Solifenacin—Feeling abnormal—Lisinopril—systemic scleroderma	0.000295	0.00124	CcSEcCtD
Solifenacin—Pruritus—Leflunomide—systemic scleroderma	0.000295	0.00124	CcSEcCtD
Solifenacin—Connective tissue disorder—Prednisone—systemic scleroderma	0.000294	0.00124	CcSEcCtD
Solifenacin—Gastrointestinal pain—Lisinopril—systemic scleroderma	0.000293	0.00123	CcSEcCtD
Solifenacin—Dysuria—Methotrexate—systemic scleroderma	0.000293	0.00123	CcSEcCtD
Solifenacin—Dizziness—Azathioprine—systemic scleroderma	0.000292	0.00123	CcSEcCtD
Solifenacin—Asthenia—Mycophenolic acid—systemic scleroderma	0.000286	0.0012	CcSEcCtD
Solifenacin—Urticaria—Lisinopril—systemic scleroderma	0.000285	0.0012	CcSEcCtD
Solifenacin—Abdominal pain—Lisinopril—systemic scleroderma	0.000283	0.00119	CcSEcCtD
Solifenacin—Pruritus—Mycophenolic acid—systemic scleroderma	0.000282	0.00118	CcSEcCtD
Solifenacin—Vomiting—Azathioprine—systemic scleroderma	0.000281	0.00118	CcSEcCtD
Solifenacin—Eye disorder—Prednisone—systemic scleroderma	0.00028	0.00118	CcSEcCtD
Solifenacin—Somnolence—Mycophenolate mofetil—systemic scleroderma	0.000279	0.00117	CcSEcCtD
Solifenacin—Infestation NOS—Methotrexate—systemic scleroderma	0.000279	0.00117	CcSEcCtD
Solifenacin—Infestation—Methotrexate—systemic scleroderma	0.000279	0.00117	CcSEcCtD
Solifenacin—Rash—Azathioprine—systemic scleroderma	0.000279	0.00117	CcSEcCtD
Solifenacin—Dermatitis—Azathioprine—systemic scleroderma	0.000278	0.00117	CcSEcCtD
Solifenacin—Depression—Methotrexate—systemic scleroderma	0.000278	0.00117	CcSEcCtD
Solifenacin—Headache—Azathioprine—systemic scleroderma	0.000277	0.00116	CcSEcCtD
Solifenacin—Dyspepsia—Mycophenolate mofetil—systemic scleroderma	0.000276	0.00116	CcSEcCtD
Solifenacin—Dizziness—Leflunomide—systemic scleroderma	0.000276	0.00116	CcSEcCtD
Solifenacin—Renal failure—Methotrexate—systemic scleroderma	0.000274	0.00115	CcSEcCtD
Solifenacin—Decreased appetite—Mycophenolate mofetil—systemic scleroderma	0.000273	0.00115	CcSEcCtD
Solifenacin—Angiopathy—Prednisone—systemic scleroderma	0.000272	0.00114	CcSEcCtD
Solifenacin—Gastrointestinal disorder—Mycophenolate mofetil—systemic scleroderma	0.000271	0.00114	CcSEcCtD
Solifenacin—Immune system disorder—Prednisone—systemic scleroderma	0.000271	0.00114	CcSEcCtD
Solifenacin—Constipation—Mycophenolate mofetil—systemic scleroderma	0.000269	0.00113	CcSEcCtD
Solifenacin—Vomiting—Leflunomide—systemic scleroderma	0.000265	0.00112	CcSEcCtD
Solifenacin—Hypersensitivity—Lisinopril—systemic scleroderma	0.000264	0.00111	CcSEcCtD
Solifenacin—Hepatobiliary disease—Methotrexate—systemic scleroderma	0.000264	0.00111	CcSEcCtD
Solifenacin—Dizziness—Mycophenolic acid—systemic scleroderma	0.000263	0.00111	CcSEcCtD
Solifenacin—Rash—Leflunomide—systemic scleroderma	0.000263	0.00111	CcSEcCtD
Solifenacin—Dermatitis—Leflunomide—systemic scleroderma	0.000263	0.00111	CcSEcCtD
Solifenacin—Mental disorder—Prednisone—systemic scleroderma	0.000263	0.0011	CcSEcCtD
Solifenacin—Nausea—Azathioprine—systemic scleroderma	0.000262	0.0011	CcSEcCtD
Solifenacin—Headache—Leflunomide—systemic scleroderma	0.000261	0.0011	CcSEcCtD
Solifenacin—Malnutrition—Prednisone—systemic scleroderma	0.000261	0.0011	CcSEcCtD
Solifenacin—Feeling abnormal—Mycophenolate mofetil—systemic scleroderma	0.000259	0.00109	CcSEcCtD
Solifenacin—Asthenia—Lisinopril—systemic scleroderma	0.000257	0.00108	CcSEcCtD
Solifenacin—Gastrointestinal pain—Mycophenolate mofetil—systemic scleroderma	0.000257	0.00108	CcSEcCtD
Solifenacin—Pruritus—Lisinopril—systemic scleroderma	0.000254	0.00107	CcSEcCtD
Solifenacin—Vomiting—Mycophenolic acid—systemic scleroderma	0.000253	0.00106	CcSEcCtD
Solifenacin—Rash—Mycophenolic acid—systemic scleroderma	0.000251	0.00106	CcSEcCtD
Solifenacin—Dermatitis—Mycophenolic acid—systemic scleroderma	0.000251	0.00105	CcSEcCtD
Solifenacin—Urticaria—Mycophenolate mofetil—systemic scleroderma	0.00025	0.00105	CcSEcCtD
Solifenacin—Headache—Mycophenolic acid—systemic scleroderma	0.000249	0.00105	CcSEcCtD
Solifenacin—Pharyngitis—Methotrexate—systemic scleroderma	0.000249	0.00105	CcSEcCtD
Solifenacin—Abdominal pain—Mycophenolate mofetil—systemic scleroderma	0.000248	0.00104	CcSEcCtD
Solifenacin—Nausea—Leflunomide—systemic scleroderma	0.000248	0.00104	CcSEcCtD
Solifenacin—Urinary tract disorder—Methotrexate—systemic scleroderma	0.000247	0.00104	CcSEcCtD
Solifenacin—Vision blurred—Prednisone—systemic scleroderma	0.000246	0.00103	CcSEcCtD
Solifenacin—Urethral disorder—Methotrexate—systemic scleroderma	0.000246	0.00103	CcSEcCtD
Solifenacin—Angioedema—Prednisone—systemic scleroderma	0.000238	0.001	CcSEcCtD
Solifenacin—Dizziness—Lisinopril—systemic scleroderma	0.000237	0.000997	CcSEcCtD
Solifenacin—Erythema multiforme—Methotrexate—systemic scleroderma	0.000237	0.000996	CcSEcCtD
Solifenacin—Nausea—Mycophenolic acid—systemic scleroderma	0.000236	0.000994	CcSEcCtD
Solifenacin—Eye disorder—Methotrexate—systemic scleroderma	0.000234	0.000984	CcSEcCtD
Solifenacin—Cardiac disorder—Methotrexate—systemic scleroderma	0.000232	0.000978	CcSEcCtD
Solifenacin—Hypersensitivity—Mycophenolate mofetil—systemic scleroderma	0.000231	0.000973	CcSEcCtD
Solifenacin—Vomiting—Lisinopril—systemic scleroderma	0.000228	0.000959	CcSEcCtD
Solifenacin—Angiopathy—Methotrexate—systemic scleroderma	0.000227	0.000956	CcSEcCtD
Solifenacin—Immune system disorder—Methotrexate—systemic scleroderma	0.000226	0.000952	CcSEcCtD
Solifenacin—Rash—Lisinopril—systemic scleroderma	0.000226	0.000951	CcSEcCtD
Solifenacin—Dermatitis—Lisinopril—systemic scleroderma	0.000226	0.00095	CcSEcCtD
Solifenacin—Mediastinal disorder—Methotrexate—systemic scleroderma	0.000226	0.000949	CcSEcCtD
Solifenacin—Asthenia—Mycophenolate mofetil—systemic scleroderma	0.000225	0.000948	CcSEcCtD
Solifenacin—Hypertension—Prednisone—systemic scleroderma	0.000225	0.000947	CcSEcCtD
Solifenacin—Headache—Lisinopril—systemic scleroderma	0.000225	0.000945	CcSEcCtD
Solifenacin—Pruritus—Mycophenolate mofetil—systemic scleroderma	0.000222	0.000935	CcSEcCtD
Solifenacin—Unspecified disorder of skin and subcutaneous tissue—Prednisone—systemic scleroderma	0.000221	0.000928	CcSEcCtD
Solifenacin—Mental disorder—Methotrexate—systemic scleroderma	0.000219	0.000923	CcSEcCtD
Solifenacin—Malnutrition—Methotrexate—systemic scleroderma	0.000218	0.000917	CcSEcCtD
Solifenacin—Dysgeusia—Methotrexate—systemic scleroderma	0.000214	0.000898	CcSEcCtD
Solifenacin—Nausea—Lisinopril—systemic scleroderma	0.000213	0.000896	CcSEcCtD
Solifenacin—Anaphylactic shock—Prednisone—systemic scleroderma	0.000213	0.000896	CcSEcCtD
Solifenacin—Infection—Prednisone—systemic scleroderma	0.000212	0.00089	CcSEcCtD
Solifenacin—Nervous system disorder—Prednisone—systemic scleroderma	0.000209	0.000878	CcSEcCtD
Solifenacin—Tachycardia—Prednisone—systemic scleroderma	0.000208	0.000874	CcSEcCtD
Solifenacin—Dizziness—Mycophenolate mofetil—systemic scleroderma	0.000208	0.000874	CcSEcCtD
Solifenacin—Skin disorder—Prednisone—systemic scleroderma	0.000207	0.00087	CcSEcCtD
Solifenacin—Vision blurred—Methotrexate—systemic scleroderma	0.000205	0.000864	CcSEcCtD
Solifenacin—Vomiting—Mycophenolate mofetil—systemic scleroderma	0.0002	0.00084	CcSEcCtD
Solifenacin—Rash—Mycophenolate mofetil—systemic scleroderma	0.000198	0.000833	CcSEcCtD
Solifenacin—Dermatitis—Mycophenolate mofetil—systemic scleroderma	0.000198	0.000832	CcSEcCtD
Solifenacin—Headache—Mycophenolate mofetil—systemic scleroderma	0.000197	0.000828	CcSEcCtD
Solifenacin—Cough—Methotrexate—systemic scleroderma	0.00019	0.0008	CcSEcCtD
Solifenacin—Dyspepsia—Prednisone—systemic scleroderma	0.000187	0.000788	CcSEcCtD
Solifenacin—Nausea—Mycophenolate mofetil—systemic scleroderma	0.000187	0.000785	CcSEcCtD
Solifenacin—Decreased appetite—Prednisone—systemic scleroderma	0.000185	0.000779	CcSEcCtD
Solifenacin—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—systemic scleroderma	0.000184	0.000775	CcSEcCtD
Solifenacin—Fatigue—Prednisone—systemic scleroderma	0.000184	0.000772	CcSEcCtD
Solifenacin—Constipation—Prednisone—systemic scleroderma	0.000182	0.000766	CcSEcCtD
Solifenacin—Confusional state—Methotrexate—systemic scleroderma	0.000179	0.000755	CcSEcCtD
Solifenacin—Anaphylactic shock—Methotrexate—systemic scleroderma	0.000178	0.000748	CcSEcCtD
Solifenacin—Infection—Methotrexate—systemic scleroderma	0.000177	0.000744	CcSEcCtD
Solifenacin—Feeling abnormal—Prednisone—systemic scleroderma	0.000175	0.000738	CcSEcCtD
Solifenacin—Nervous system disorder—Methotrexate—systemic scleroderma	0.000175	0.000734	CcSEcCtD
Solifenacin—Gastrointestinal pain—Prednisone—systemic scleroderma	0.000174	0.000732	CcSEcCtD
Solifenacin—Skin disorder—Methotrexate—systemic scleroderma	0.000173	0.000727	CcSEcCtD
Solifenacin—Urticaria—Prednisone—systemic scleroderma	0.000169	0.000711	CcSEcCtD
Solifenacin—Abdominal pain—Prednisone—systemic scleroderma	0.000168	0.000708	CcSEcCtD
Solifenacin—Somnolence—Methotrexate—systemic scleroderma	0.000158	0.000665	CcSEcCtD
Solifenacin—Hypersensitivity—Prednisone—systemic scleroderma	0.000157	0.00066	CcSEcCtD
Solifenacin—Dyspepsia—Methotrexate—systemic scleroderma	0.000157	0.000659	CcSEcCtD
Solifenacin—Decreased appetite—Methotrexate—systemic scleroderma	0.000155	0.000651	CcSEcCtD
Solifenacin—Gastrointestinal disorder—Methotrexate—systemic scleroderma	0.000154	0.000646	CcSEcCtD
Solifenacin—Fatigue—Methotrexate—systemic scleroderma	0.000153	0.000645	CcSEcCtD
Solifenacin—Asthenia—Prednisone—systemic scleroderma	0.000153	0.000643	CcSEcCtD
Solifenacin—Pruritus—Prednisone—systemic scleroderma	0.000151	0.000634	CcSEcCtD
Solifenacin—Feeling abnormal—Methotrexate—systemic scleroderma	0.000147	0.000617	CcSEcCtD
Solifenacin—Gastrointestinal pain—Methotrexate—systemic scleroderma	0.000146	0.000612	CcSEcCtD
Solifenacin—Urticaria—Methotrexate—systemic scleroderma	0.000141	0.000595	CcSEcCtD
Solifenacin—Dizziness—Prednisone—systemic scleroderma	0.000141	0.000592	CcSEcCtD
Solifenacin—Abdominal pain—Methotrexate—systemic scleroderma	0.000141	0.000592	CcSEcCtD
Solifenacin—Vomiting—Prednisone—systemic scleroderma	0.000135	0.000569	CcSEcCtD
Solifenacin—Rash—Prednisone—systemic scleroderma	0.000134	0.000565	CcSEcCtD
Solifenacin—Dermatitis—Prednisone—systemic scleroderma	0.000134	0.000564	CcSEcCtD
Solifenacin—Headache—Prednisone—systemic scleroderma	0.000133	0.000561	CcSEcCtD
Solifenacin—Hypersensitivity—Methotrexate—systemic scleroderma	0.000131	0.000551	CcSEcCtD
Solifenacin—Asthenia—Methotrexate—systemic scleroderma	0.000128	0.000537	CcSEcCtD
Solifenacin—Nausea—Prednisone—systemic scleroderma	0.000126	0.000532	CcSEcCtD
Solifenacin—Pruritus—Methotrexate—systemic scleroderma	0.000126	0.00053	CcSEcCtD
Solifenacin—Dizziness—Methotrexate—systemic scleroderma	0.000118	0.000495	CcSEcCtD
Solifenacin—Vomiting—Methotrexate—systemic scleroderma	0.000113	0.000476	CcSEcCtD
Solifenacin—Rash—Methotrexate—systemic scleroderma	0.000112	0.000472	CcSEcCtD
Solifenacin—Dermatitis—Methotrexate—systemic scleroderma	0.000112	0.000471	CcSEcCtD
Solifenacin—Headache—Methotrexate—systemic scleroderma	0.000111	0.000469	CcSEcCtD
Solifenacin—Nausea—Methotrexate—systemic scleroderma	0.000106	0.000445	CcSEcCtD
